Baseline Prepulse Inhibition Dependency of Orexin A and REM Sleep Deprivation

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2024 Mar 1

PMID 38427059

Authors

Pinar Oz

Osman Kamali

Hacer Begum Saka

Ceren Gor

Ismail Tayfun Uzbay

Affiliations

Soon will be listed here.

Abstract

Rationale: Prepulse inhibition (PPI) impairment reflects sensorimotor gating problems, i.e. in schizophrenia. This study aims to enlighten the role of orexinergic regulation on PPI in a psychosis-like model.

Objectives: In order to understand the impact of orexinergic innervation on PPI and how it is modulated by age and baseline PPI (bPPI), chronic orexin A (OXA) injections was carried on non-sleep-deprived and sleep-deprived rats that are grouped by their bPPI.

Methods: bPPI measurements were carried on male Wistar rats on P45 or P90 followed by grouping into low-PPI and high-PPI rats. The rats were injected with OXA twice per day for four consecutive days starting on P49 or P94, while the control groups received saline injections. 72 h REMSD was carried on via modified multiple platform technique on P94 and either OXA or saline was injected during REMSD. PPI tests were carried out 30 min. after the last injection.

Results: Our previous study with acute OXA injection after REMSD without bPPI grouping revealed that low OXA doses might improve REMSD-induced PPI impairment. Our current results present three important conclusions: (1) The effect of OXA on PPI is bPPI-dependent and age-dependent. (2) The effect of REMSD is bPPI-dependent. (3) The effect of OXA on PPI after REMSD also depends on bPPI.

Conclusion: Orexinergic regulation of PPI response with and without REMSD can be predicted by bPPI levels. Our findings provide potential insights into the regulation of sensorimotor gating by sleep/wakefulness systems and present potential therapeutic targets for the disorders, where PPI is disturbed.

References

Demidova A, Kahl E, Fendt M . Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 116:110517. DOI: 10.1016/j.pnpbp.2022.110517. View

Mena A, Ruiz-Salas J, Puentes A, Dorado I, Ruiz-Veguilla M, De la Casa L . Reduced Prepulse Inhibition as a Biomarker of Schizophrenia. Front Behav Neurosci. 2016; 10:202. PMC: 5067522. DOI: 10.3389/fnbeh.2016.00202. View

DePorter D, Coborn J, Teske J . Partial Sleep Deprivation Reduces the Efficacy of Orexin-A to Stimulate Physical Activity and Energy Expenditure. Obesity (Silver Spring). 2017; 25(10):1716-1722. DOI: 10.1002/oby.21944. View

Ran M, Wu W, Li J, Yang C, Ouyang P, Deng J . Reduction of orexin-A is responsible for prolonged emergence of the rat subjected to sleep deprivation from isoflurane anesthesia. CNS Neurosci Ther. 2015; 21(3):298-300. PMC: 6495159. DOI: 10.1111/cns.12380. View

GRAHAM F . Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology. 1975; 12(3):238-48. DOI: 10.1111/j.1469-8986.1975.tb01284.x. View

Briggs C, Hirasawa M, Semba K . Sleep Deprivation Distinctly Alters Glutamate Transporter 1 Apposition and Excitatory Transmission to Orexin and MCH Neurons. J Neurosci. 2018; 38(10):2505-2518. PMC: 6705895. DOI: 10.1523/JNEUROSCI.2179-17.2018. View

Nishino S, Ripley B, Mignot E, Benson K, Zarcone V . CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002; 110(1):1-7. DOI: 10.1016/s0165-1781(02)00032-x. View

Kumari V, Ettinger U . Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update. Schizophr Res. 2020; 221:4-11. DOI: 10.1016/j.schres.2020.03.064. View

Tiwari A, Brandl E, Zai C, Goncalves V, Chowdhury N, Freeman N . Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. World J Biol Psychiatry. 2015; 17(3):221-9. DOI: 10.3109/15622975.2015.1076173. View

10.

Braff D, Geyer M . Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry. 1990; 47(2):181-8. DOI: 10.1001/archpsyc.1990.01810140081011. View

11.

Mehta R, Khanday M, Mallick B . REM sleep loss associated changes in orexin-A levels in discrete brain areas in rats. Neurosci Lett. 2015; 590:62-7. DOI: 10.1016/j.neulet.2015.01.067. View

12.

Basoglu C, Oner O, Gunes C, Semiz U, Ates A, Algul A . Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int Clin Psychopharmacol. 2011; 25(3):165-71. DOI: 10.1097/YIC.0b013e3283377850. View

13.

Broberg B, Oranje B, Glenthoj B, Fejgin K, Plath N, Bastlund J . Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia--gating of auditory-evoked potentials and prepulse inhibition. Behav Brain Res. 2010; 213(2):142-7. DOI: 10.1016/j.bbr.2010.04.026. View

14.

Lu J, Huang M, Li J, Jin K, Li H, Mou T . Changes of Hypocretin (Orexin) System in Schizophrenia: From Plasma to Brain. Schizophr Bull. 2021; 47(5):1310-1319. PMC: 8379539. DOI: 10.1093/schbul/sbab042. View

15.

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

16.

Monda V, Salerno M, Sessa F, Bernardini R, Valenzano A, Marsala G . Functional Changes of Orexinergic Reaction to Psychoactive Substances. Mol Neurobiol. 2018; 55(8):6362-6368. DOI: 10.1007/s12035-017-0865-z. View

17.

Deutch A, Bubser M . The orexins/hypocretins and schizophrenia. Schizophr Bull. 2007; 33(6):1277-83. PMC: 2779882. DOI: 10.1093/schbul/sbm096. View

18.

Deadwyler S, Porrino L, Siegel J, Hampson R . Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007; 27(52):14239-47. PMC: 6673447. DOI: 10.1523/JNEUROSCI.3878-07.2007. View

19.

Petrovsky N, Ettinger U, Hill A, Frenzel L, Meyhofer I, Wagner M . Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. J Neurosci. 2014; 34(27):9134-40. PMC: 6608255. DOI: 10.1523/JNEUROSCI.0904-14.2014. View

20.

Chen P, Chen C, Chang C, Kao C, Lu M, Lin S . Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. Int J Neuropsychopharmacol. 2018; 22(1):28-36. PMC: 6313111. DOI: 10.1093/ijnp/pyy075. View